A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection - Trial NCT06311734
Access comprehensive clinical trial information for NCT06311734 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. and is currently Recruitment Completed. The study focuses on Chronic Hepatitis B. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Timeline & Enrollment
Phase 1
Nov 01, 2021
May 01, 2024
Primary Outcome
Number of Participants With Adverse Events (AEs)
Summary
To Evaluate the Tolerability and Pharmacokinetics of LW231 Tablets in Single-center,
 Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase
 Ia Clinical Trials in Healthy Subjects .
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06311734
Non-Device Trial